Abstract
TPS316 Background: Studies in cancer survivors have shown a 15-50% incidence of cognitive impairment following chemotherapy, with up to 70% self reporting cognitive impairment (Vardy J, et al. Ann Oncol 19:623-9, 2008). There are no proven treatments to manage this problem. Cognitive rehabilitation is effective in other patient groups and a single arm pilot study of cognitive behavior therapy in cancer survivors showed promise (Ferguson RJ, et al. Psycho-oncology 16:772-7, 2007). Our randomized controlled trial evaluates a cognitive rehabilitation program (CRP) in cancer survivors with solid tumors (excluding primary brain tumors), self-reporting cognitive impairment following curative chemotherapy. Our primary hypothesis is that a CRP will improve self reported cognitive function. Secondary hypotheses are that a CRP can improve objective neuropsychological performance and patient reported outcomes including: (i) quality of life; (ii) depression and anxiety; (iii) stress; (iv) fatigue. Methods: We are recruiting cancer survivors with self-reported cognitive impairment, as indicated by changes in concentration and memory on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Cognitive Functioning scale. Participants must have completed potentially curative chemotherapy within 6 to 60 months and have no cancer recurrence. The intervention arm perform a home-based, internet CRP for 4× 40 minute sessions per week for 15 weeks. Both intervention and control arms participate in a 30-minute scripted teleconference discussing strategies to manage cognitive impairment. Participants complete neuropsychological tests and questionnaires evaluating patient reported outcomes at baseline, post intervention and 6 months post intervention. Primary endpoint is self-reported cognitive function assessed by the Functional Assessment of Cancer Treatment–Cognition questionnaire. Sample size is 280, with 20 patients accrued to date. No significant financial relationships to disclose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
